Lisata Therapeutics Reports $4.7 Million Net Loss in Q1 2025, Focuses on Certepetide Trials

Lisata Therapeutics, Inc. reported a net loss of $4.7 million for the first quarter of 2025, a decrease from the $5.4 million loss recorded in the same period of 2024. The company's total operating expenses fell to $5.8 million, down 11.4% from $6.6 million year-over-year. This reduction was primarily driven by a 19.7% decrease in research and development expenses, which amounted to approximately $2.6 million, attributed to lower clinical research organization costs and reduced spending on chemistry, manufacturing, and controls. General and administrative expenses also saw a slight decline, totaling $3.2 million compared to $3.4 million in the prior year.

In terms of financial position, Lisata's cash, cash equivalents, and marketable securities totaled approximately $25.8 million as of March 31, 2025, down from $43.3 million at the end of 2024. The company reported a working capital of about $24.8 million and stockholders' equity of approximately $25.4 million. The decrease in cash reserves was influenced by the company's ongoing operational losses, although it managed to generate $9.4 million in cash from investing activities, primarily through net sales of marketable securities.

Lisata Therapeutics continues to focus on its investigational product, certepetide, which is currently undergoing several Phase 2 clinical trials for various solid tumors, including metastatic pancreatic ductal adenocarcinoma. The company has made strategic decisions to delay certain clinical activities to optimize resource allocation, including putting the initiation of the FORTIFIDE study on hold while exploring more efficient approaches. The company is also actively seeking additional financing options to support its long-term liquidity needs, which may include public or private equity offerings, partnerships, or asset sales.

The company has not recognized any revenue for the three months ended March 31, 2025, consistent with the previous year. Lisata's operational focus remains on advancing its clinical programs and exploring potential out-licensing opportunities to enhance its product pipeline. The management anticipates that its current cash reserves will be sufficient to fund operations for at least the next 12 months, although it acknowledges the challenges of raising capital in a volatile market environment.

Overall, Lisata Therapeutics is navigating a critical phase in its development, with ongoing clinical trials and a focus on optimizing its financial resources while managing operational costs. The company remains committed to its goal of developing innovative therapies for solid tumors, despite the financial challenges it faces.